Relation of platelet inactivation with intravenous glycoprotein IIb/IIIa antagonists to major bleeding (from the GOLD study)

American Journal of Cardiology

Volumn 89, Issue 12, 2002, Pages 1429-1431

  Tamberella, Michael R ^a   Bhatt, Deepak L ^a   Chew, Derek P ^a   Kereiakes, Dean J ^b   Topol, Eric J ^a   Steinhubl, Steven R ^c  

^a LERNER RESEARCH INSTITUTE   (United States)

^b Ohio Heart and Vascular Center   (United States)

^c Lackland Airforce Base ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; FIBRINOGEN RECEPTOR ANTAGONIST;

ANTICOAGULATION; BLEEDING; BLOOD CLOTTING TIME; FUNCTION TEST; HUMAN; PRIORITY JOURNAL; REDUCTION; SHORT SURVEY; THROMBOCYTE ACTIVATION; THROMBOCYTE FUNCTION;

EID: 0037097389     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(02)02362-7     Document Type: Article

References (6)

1. Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention. Results of the GOLD (AU-Assessing Ultegra) multicenter study
2. The rapid platelet function assay: An automated and quantitative cartridge-based method
3. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty
4. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization
5. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. The EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting
6. Defining the optimal activated clotting time during percutaneous coronary intervention - Aggregate results from 6 randomized, controlled trials